Sanofi India shines on entering into partnership with Cipla
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sanofi India is currently trading at Rs. 8049.00, up by 338.15 points or 4.39% from its previous closing of Rs. 7710.85 on the BSE.
The scrip opened at Rs. 8000.00 and has touched a high and low of Rs. 8117.25 and Rs. 7849.25 respectively. So far 2732 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 9370.35 on 23-Feb-2024 and a 52 week low of Rs. 5329.70 on 03-May-2023.
Last one week high and low of the scrip stood at Rs. 8117.25 and Rs. 7517.10 respectively. The current market cap of the company is Rs. 18594.92 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 28.82% and 10.78% respectively.
Sanofi India (SIL) and Sanofi Healthcare India (together referred as ‘Sanofi India’) and Cipla have entered into an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India.
As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category. While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Sanofi India is a global biopharmaceutical company focused on human health.
